Coverage of issues such as drug prices and insurance supply chains that impact people’s ability to access medicine and therapies.
More
How Switzerland became liberal on abortion – without noticing
This content was published on
From 2027 Swiss health insurers will cover the full cost of abortions. The change passed through parliament almost unnoticed.
Swiss drugmakers face mixed fortunes amid Trump’s tariff upheaval
This content was published on
Pharma giants may escape the worst of the import tariffs threatened by the US. But Switzerland’s smaller developers face a more uncertain future.
How a clash with Roche exposed cracks in Swiss drug pricing system
This content was published on
Switzerland’s new process to speed up patient access to the latest drugs hit its first major hurdle in a clash with Roche.
Potential US tariff exemption for Swiss pharma is not necessarily a boon
This content was published on
Donald Trump is pressuring the pharma industry with tariffs. But experts say that tariffs will have less impact on the industry than pricing.
Sandoz board chair ‘convinced that common sense will ultimately prevail’ on US pharma tariffs
This content was published on
In an exclusive interview with Swissinfo, Sandoz chair Gilbert Ghostine says he remains optimistic despite looming tariff hikes.
Rare diseases take centre stage at global health summit
This content was published on
Rare diseases have been recognised as a global health priority for the first time. How could this impact access to life-saving treatment?
Despite Trump’s bold claims, medicine prices in Europe won’t rise anytime soon
This content was published on
US President Trump has taken aim at Europe for undercharging for medicine. But raising prices in Europe would face strong pushback.
Swiss regulator and media clash over weight-loss drugs
This content was published on
Swissmedic has taken legal action against media for alleged unauthorised advertising of weight-loss drugs. Swiss media say this is censorship.
How drug prices are negotiated in Switzerland and beyond
This content was published on
Switzerland’s pharmaceutical sector supplies drugs worldwide, but not all countries receive them with the same price tag. Here’s why.
How private equity oversees the ethics of drug research
This content was published on
Many drug trials are vetted by companies with ties to the drugmakers, raising concerns about conflicts of interest and patient safety.
When diagnosing a disease does more harm than good
This content was published on
Switzerland has the highest number of MRI scanners per person in Europe. But more screening doesn’t always lead to better health outcomes.
Global concern over measles is rising. Should Switzerland worry?
This content was published on
Measles is making a global comeback. In Switzerland, a crisis is unlikely – but authorities warn a strong vaccination rate remains crucial.
Swiss regulator and media clash over weight-loss drugs
This content was published on
Swissmedic has taken legal action against media for alleged unauthorised advertising of weight-loss drugs. Swiss media say this is censorship.
Medicines regulators weigh hope and hype with new Alzheimer’s drugs
This content was published on
Swissmedic is expected to decide on the approval of the first new drug for Alzheimer’s disease in two decades. The decision won’t be easy.
This content was published on
Sales of counterfeit drugs are booming around the world, putting thousands of lives at risk. Why is it so hard to stem the tide of fake medicine?
Swiss drugmakers face mixed fortunes amid Trump’s tariff upheaval
This content was published on
Pharma giants may escape the worst of the import tariffs threatened by the US. But Switzerland’s smaller developers face a more uncertain future.
This content was published on
Ypsomed CEO explains why US tariffs are not a worry and why he sees more growth from diabetes and obesity treatments such as Ozempic.
Potential US tariff exemption for Swiss pharma is not necessarily a boon
This content was published on
Donald Trump is pressuring the pharma industry with tariffs. But experts say that tariffs will have less impact on the industry than pricing.
How US tariffs could disrupt the generic drugs supply chain
This content was published on
US tariffs on generics could raise drug prices and accentuate shortages. That’s not what US President Donald Trump had in mind.
Sandoz board chair ‘convinced that common sense will ultimately prevail’ on US pharma tariffs
This content was published on
In an exclusive interview with Swissinfo, Sandoz chair Gilbert Ghostine says he remains optimistic despite looming tariff hikes.
This content was published on
Looming US pharma tariffs could challenge the status quo in pharmaceutical hubs like Switzerland as investment shifts to the US.
How Switzerland became liberal on abortion – without noticing
This content was published on
From 2027 Swiss health insurers will cover the full cost of abortions. The change passed through parliament almost unnoticed.
Swiss drugmakers face mixed fortunes amid Trump’s tariff upheaval
This content was published on
Pharma giants may escape the worst of the import tariffs threatened by the US. But Switzerland’s smaller developers face a more uncertain future.
When diagnosing a disease does more harm than good
This content was published on
Switzerland has the highest number of MRI scanners per person in Europe. But more screening doesn’t always lead to better health outcomes.
Swiss drugmakers face mixed fortunes amid Trump’s tariff upheaval
This content was published on
Pharma giants may escape the worst of the import tariffs threatened by the US. But Switzerland’s smaller developers face a more uncertain future.
How private equity oversees the ethics of drug research
This content was published on
Many drug trials are vetted by companies with ties to the drugmakers, raising concerns about conflicts of interest and patient safety.
How a clash with Roche exposed cracks in Swiss drug pricing system
This content was published on
Switzerland’s new process to speed up patient access to the latest drugs hit its first major hurdle in a clash with Roche.
This content was published on
Ypsomed CEO explains why US tariffs are not a worry and why he sees more growth from diabetes and obesity treatments such as Ozempic.
When diagnosing a disease does more harm than good
This content was published on
Switzerland has the highest number of MRI scanners per person in Europe. But more screening doesn’t always lead to better health outcomes.
Potential US tariff exemption for Swiss pharma is not necessarily a boon
This content was published on
Donald Trump is pressuring the pharma industry with tariffs. But experts say that tariffs will have less impact on the industry than pricing.
Can Saudi Arabia’s billions unlock the secrets to a longer, healthier life?
This content was published on
Longevity has been an underfunded area of biotech research but that is changing thanks to an unlikely source: Saudi Arabia.
How US tariffs could disrupt the generic drugs supply chain
This content was published on
US tariffs on generics could raise drug prices and accentuate shortages. That’s not what US President Donald Trump had in mind.
Sandoz board chair ‘convinced that common sense will ultimately prevail’ on US pharma tariffs
This content was published on
In an exclusive interview with Swissinfo, Sandoz chair Gilbert Ghostine says he remains optimistic despite looming tariff hikes.
Global concern over measles is rising. Should Switzerland worry?
This content was published on
Measles is making a global comeback. In Switzerland, a crisis is unlikely – but authorities warn a strong vaccination rate remains crucial.
This content was published on
Nearly 30 years ago an academic paper wrongly linked autism to a measles vaccine. The impacts are still being felt today.
Rare diseases take centre stage at global health summit
This content was published on
Rare diseases have been recognised as a global health priority for the first time. How could this impact access to life-saving treatment?
Novartis bets on ageing as next frontier in drug development
This content was published on
Swiss pharma giant Novartis is diving into research on ageing to tap the growing market for drugs that help keep older adults healthy.
Despite Trump’s bold claims, medicine prices in Europe won’t rise anytime soon
This content was published on
US President Trump has taken aim at Europe for undercharging for medicine. But raising prices in Europe would face strong pushback.
Chinese biotechs eye Swiss collaboration as relations with US sour
This content was published on
With growing uncertainty in the US, Chinese companies are swooping in to present themselves as stable, open partners to the Swiss biotech sector.
This content was published on
People have come to Switzerland for centuries in search of the fountain of youth. How did the country become a magnet for longevity seekers?
Longevity clinics: modern-day snake oil or the key to healthy ageing?
This content was published on
Scientists have yet to find the elixir of life but this hasn’t stopped longevity clinics from selling treatments, pills and gadgets that claim to slow ageing.
This content was published on
Looming US pharma tariffs could challenge the status quo in pharmaceutical hubs like Switzerland as investment shifts to the US.
In Switzerland more people are being referred to electrical therapies or psychedelic-assisted psychotherapy. Are there similar approaches where you live?
Electric touch: neurostimulation’s comeback in psychiatry
This content was published on
Faced with a lack of breakthroughs in treating mental health disorders, older methods such as electrical-based therapies are experiencing a revival.
This content was published on
Gene therapy companies have faced numerous setbacks over the last few years. What will it take for gene therapies to fulfill their promise?
‘It’s political’: why some people refuse to have a smartphone
This content was published on
Almost two decades after the first iPhone, not everyone is ready to go fully digital. We talk to three people sceptical of the always-online life.
Lost stem cells: the scandal of a Swiss cord blood bank
This content was published on
Imagine placing all your hopes on your baby’s stem cells to save their life or yours, only to fear seeing that hope vanish along with your child’s cells.
What the Swiss don’t know about sexually transmitted infections
This content was published on
Many Swiss are not that savvy about sexually transmitted infections. Even so, a programme to inform people about STIs is being cut.
